Skip to main
PCSA

Processa Pharmaceuticals (PCSA) Stock Forecast & Price Target

Processa Pharmaceuticals (PCSA) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Processa Pharmaceuticals Inc. has demonstrated a narrowed net loss per share estimate for 2026, decreasing from $0.20 to $0.15, indicating improvements in financial performance while accounting for an increased outstanding share count. The potential for significant value increase is highlighted by upcoming positive interim data from the mid-stage trial of its lead product, NGC-Cap. Additionally, the company has secured a strategic investment and is exploring corporate cryptocurrency treasury strategies, reflecting proactive financial management and growth initiatives.

Bears say

Processa Pharmaceuticals is anticipated to report a full-year net loss of $0.43 per share for 2025, reflecting concerns over regulatory approvals and the potential for increased competition that may hinder pricing and market penetration. The company's current financial performance includes a recent net loss of $0.25 per share, slightly above the projected net loss of $0.23 per share, signaling ongoing financial challenges. Additionally, risks associated with partnerships and the prospect of dilution in the near to medium term further contribute to a negative outlook on the stock.

Processa Pharmaceuticals (PCSA) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Processa Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Processa Pharmaceuticals (PCSA) Forecast

Analysts have given Processa Pharmaceuticals (PCSA) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Processa Pharmaceuticals (PCSA) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Processa Pharmaceuticals (PCSA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.